The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works

tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?

Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

Hampel, H. J., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 630 · see citing works

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614 · see citing works

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study

Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · see citing works

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 487 · see citing works

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works

Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology

Olsson, A., Vanderstichele, H., Andreasen, N., Meyer, G. D., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 424 · see citing works

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

Mattsson, N., Andréasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., Bocchio‐Chiavetto, L., Blankenstein, M. A., Carrillo, M. C., Chalbot, S., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2243 · Cited by 409 · see citing works

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287 · see citing works

Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N. C., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B. G., & Blennow, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00617-5 · Cited by 236 · see citing works

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease

Jack, C. R., Barkhof, F., Bernstein, M. A., Cantillon, M., Cole, P. E., DeCarli, C. S., Dubois, B., Duchesne, S., Fox, N. C., Frisoni, G. B., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.04.007 · Cited by 219 · see citing works

Cerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women

Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H., & Blennow, K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100529 · Cited by 214 · see citing works

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42

Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204 · see citing works

Biochemical markers in persons with preclinical familial Alzheimer disease

Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198 · see citing works

Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194 · see citing works

Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly

Stomrud, E., Hansson, O., Blennow, K., Minthon, L., & Londos, E. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000105017 · Cited by 164 · see citing works

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

Koopman, K., Bastard, N. L., Martin, J., Nagels, G., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.02.017 · Cited by 151 · see citing works

Biomarkers in Alzheimer's disease drug development

Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 145 · see citing works

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182704056 · Cited by 136 · see citing works

Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients

Zetterberg, H., Tullhög, K., Hansson, O., Minthon, L., Londos, E., & Blennow, K. (2010) · European Neurology · doi:10.1159/000311703 · Cited by 108 · see citing works

A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ ₃₈ , Aβ ₄₀ , and Aβ ₄₂ in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls

Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121471 · Cited by 105 · see citing works

Familial Alzheimer disease: Decreases in CSF Aβ 42 levels precede cognitive decline

Moonis, M., Swearer, J. M., Dayaw, M. P. E., George‐Hyslop, P. S., Rogaeva, E. A., Kawarai, T., & Pollen, D. A. (2005) · Neurology · doi:10.1212/01.wnl.0000171397.32851.bc · Cited by 95 · see citing works

Reference Measurement Procedures for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers: Definitions and Approaches With Focus on Amyloid β42

Mattsson, N., Zegers, I., Andréasson, U., Bjerke, M., Blankenstein, M. A., Bowser, R. P., Carrillo, M. C., Gobom, J., Heath, T., Jenkins, R. G., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.39 · Cited by 77 · see citing works

Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment

Mattsson, N., Portelius, E., Rolstad, S., Gustavsson, M. K., Andréasson, U., Stridsberg, M., Wallin, A., Blennow, K., & Zetterberg, H. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120019 · Cited by 74 · see citing works

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population

Johansson, P., Mattsson, N., Hansson, O., Wallin, A., Johansson, J.-O., Andréasson, U., Zetterberg, H., Blennow, K., & Svensson, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101878 · Cited by 71 · see citing works

Alzheimer CSF biomarkers in routine clinical setting

Tabaraud, F., Leman, J. P., Milor, A.-M., Roussie, J. M., Barrière, G., Tartary, M., Boutros-Toni, F., & Rigaud, M. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01592.x · Cited by 44 · see citing works

Proficiency Testing Programs for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers

Mattsson, N., Andréasson, U., Carrillo, M. C., Persson, S., Shaw, L. M. J., Zegers, I., Zetterberg, H., & Blennow, K. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.41 · Cited by 24 · see citing works

The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives

Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · see citing works

Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models

Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755 · see citing works

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293 · see citing works

Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology

Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289 · see citing works

Current state of digital biomarker technologies for real-life, home-based monitoring of cognitive function for mild cognitive impairment to mild Alzheimer disease and implications for clinical care: systematic review

Piau, A., Wild, K., Mattek, N., & Kaye, J. (2019) · Journal of Medical Internet Research · doi:10.2196/12785 · Cited by 252 · see citing works

Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach

Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D. (2018) · Brain · doi:10.1093/brain/awx352 · Cited by 220 · see citing works

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Lannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt246 · Cited by 152 · see citing works

Raman spectroscopy and machine learning for biomedical applications: Alzheimer’s disease diagnosis based on the analysis of cerebrospinal fluid

Ryzhikova, E., Ralbovsky, N. M., Sikirzhytski, V., Kazakov, O., Halámková, L., Quinn, J. F., Zimmerman, E. A., & Lednev, I. K. (2020) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2020.119188 · Cited by 131 · see citing works

The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals

Osorio, R. S., Ayappa, I. A., Mantua, J., Gumb, T., Varga, A. W., Mooney, A. M., Burschtin, O. E., Taxin, Z. H., During, E., Spector, N. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.030 · Cited by 123 · see citing works

Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders

Maffioletti, E., Tardito, D., Gennarelli, M., & Bocchio‐Chiavetto, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00075 · Cited by 121 · see citing works

Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease

Gispert, J. D., Suárez‐Calvet, M., Monté, G. C., Tucholka, A., Falcón, C., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.005 · Cited by 114 · see citing works

Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and <scp>A</scp>lzheimer disease

Agosta, F., Dalla Libera, D., Spinelli, E. G., Finardi, A., Canu, E., Bergami, A., Bocchio Chiavetto, L., Baronio, M., Comi, G., Martino, G., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24235 · Cited by 113 · see citing works

Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome?

Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102 · see citing works

Development and validation of a salivary tau biomarker in Alzheimer's disease

Pekeles, H., Qureshi, H. Y., Paudel, H. K., Schipper, H. M., Gornistky, M., & Chertkow, H. M. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.003 · Cited by 80 · see citing works

The problem of genotype and sex differences in life expectancy in transgenic AD mice

Rae, E. A., & Brown, R. E. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.002 · Cited by 75 · see citing works

CRMP2

Ip, J. P. K., Fu, A. K. Y., & Ip, N. Y. (2014) · The Neuroscientist · doi:10.1177/1073858413514278 · Cited by 77 · see citing works

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

Frölich, L., Peters, O., Lewczuk, P., Gruber, O., Teipel, S. J., Gertz, H., Jahn, H., Jessen, F., Kurz, A., Luckhaus, C., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0301-7 · Cited by 77 · see citing works

Salivary biomarkers of neurodegenerative and demyelinating diseases and biosensors for their detection

Goldoni, R., Dolci, C., Boccalari, E., Inchingolo, F., Paghi, A., Strambini, L. M., Galimberti, D., & Tartaglia, G. M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101587 · Cited by 78 · see citing works

Diagnostic Value of microRNA for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Hu, Y.-B., Li, C., Song, N., Zou, Y., Chen, S.-D., Ren, R., & Wang, G. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00013 · Cited by 59 · see citing works

The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer’s disease

de Leon, M. J., Pirraglia, E., Osorio, R. S., Glodzik, L., Saint-Louis, L. A., Kim, H.-J., Fortea, J., Fossati, S., LASKA, E. M., Siegel, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191240 · Cited by 58 · see citing works

Pathogenesis of Alzheimer's Disease: Role of Amyloid-beta and Hyperphosphorylated Tau Protein

Sajjad, R., Arif, R., Shah, A. A., Manzoor, I., & Mustafa, G. (2018) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000397 · Cited by 57 · see citing works

Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to

Henriques, A. D., Benedet, A. L., Camargos, E. F., Rosa‐Neto, P., & Nóbrega, O. D. T. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.01.002 · Cited by 54 · see citing works

Lipidomics of Alzheimer’s Disease

Touboul, D., & Gaudin, M. (2014) · Bioanalysis · doi:10.4155/bio.13.346 · Cited by 52 · see citing works

Clinical Experience with Cerebrospinal Fluid Aβ 42 , Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia

Tariciotti, L., Casadei, M., Honig, L. S., Teich, A. F., McKhann, G. M., Tosto, G., & Mayeux, R. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180548 · Cited by 46 · see citing works

Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment

Ahmad, S., Yang, W., Orellana, A., Frölich, L., de Rojas, I., Cano, A. C., Boada, M., Hernández, I., Hausner, L., Harms, A. C., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01542-4 · Cited by 39 · see citing works

Blood-based diagnosis of Alzheimer's disease using fingerprinting metabolomics based on hydrophilic interaction liquid chromatography with mass spectrometry and multivariate statistical analysis

Inoue, K., Tsuchiya, H., Takayama, T., Akatsu, H., Hashizume, Y., Yamamoto, T., Matsukawa, N., & Toyo’oka, T. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.10.022 · Cited by 35 · see citing works

Yeast buddies helping to unravel the complexity of neurodegenerative disorders

Fruhmann, G., Seynnaeve, D., Zheng, J., Ven, K., Molenberghs, S., Wilms, T., Liu, B., Winderickx, J., & Franssens, V. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.05.002 · Cited by 35 · see citing works

A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals

Bruno, D., Grothe, M. J., Nierenberg, J. J., Zetterberg, H., Blennow, K., Teipel, S. J., & Pomara, N. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.01.025 · Cited by 30 · see citing works

Endocannabinoid signals in the developmental programming of delayed-onset neuropsychiatric and metabolic illnesses

Keimpema, E., Calvigioni, D., & Harkany, T. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130117 · Cited by 28 · see citing works

Feature selective temporal prediction of Alzheimer's disease progression using hippocampus surface morphometry

Tsao, S., Gajawelli, N., Zhou, J., Shi, J., Ye, J., Wang, Y., & Leporé, N. (2017) · Brain and Behavior · doi:10.1002/brb3.733 · Cited by 18 · see citing works

Increased inflammation in BA21 brain tissue from African Americans with Alzheimer’s disease

Ferguson, S. A., Varma, V., Sloper, D. T., Panos, J., & Sarkar, S. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00512-2 · Cited by 18 · see citing works

Brain investigation and brain conceptualization.

Redolfi, A., Bosco, P., Manset, D., & Frisoni, G. B. (2013) · Europe PMC (PubMed Central) · Cited by 17 · see citing works

Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis

Michaud, T. L., Kane, R. L., McCarten, J. R., Gaugler, J. E., Nyman, J. A., & Kuntz, K. M. (2017) · PharmacoEconomics - Open · doi:10.1007/s41669-017-0054-z · Cited by 15 · see citing works

Alzheimer's and Parkinson's diseases: An environmental proteomic point of view

Demartini, D. R., Schilling, L. P., da Costa, J. C., & Carlini, C. R. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.04.014 · Cited by 12 · see citing works

A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s disease

Lannfelt, L. (2023) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v128.10316 · Cited by 11 · see citing works

Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis

Michaud, T. L., Initiative, A. D. N., Kane, R. L., McCarten, J. R., Gaugler, J. E., Nyman, J. A., & Kuntz, K. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150066 · Cited by 10 · see citing works

Hybrid Feature Selection Framework for Identification of Alzheimer�s Biomarkers

Thavavel, V., & Karthiyayini, M. (2018) · Indian Journal of Science and Technology · doi:10.17485/ijst/2018/v11i20/123310 · Cited by 11 · see citing works

Survey on Acceptance of Passive Technology Monitoring for Early Detection of Cognitive Impairment

Josephy‐Hernandez, S. E., Norise, C., Han, J., & Smith, K. M. (2020) · Digital Biomarkers · doi:10.1159/000512207 · Cited by 8 · see citing works

Cerebrospinal Fluid τ Protein in Differential Diagnosis of Alzheimer’s Disease and Vascular Dementia in Chinese population

Liu, B., Tang, Y., Shen, Y., Cen, L., & Min, H. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513507374 · Cited by 8 · see citing works

Neue diagnostische Methoden bei Demenzen

Wiltfang, J. (2015) · Der Nervenarzt · doi:10.1007/s00115-014-4177-5 · Cited by 5 · see citing works

Eliminating Bottlenecks for Efficient Bioanalysis: Practices and Applications in Drug Discovery and Development

Shou, W. Z., & Weng, N. (2014) · doi:10.4155/9781909453883 · Cited by 7 · see citing works

Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy

Cente, M., Zórad, Š., Smolek, T., Fialová, Ľ., Ivanovova, N. P., Kršková, K., Balážová, L., Škrabana, R., & Filipčík, P. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00972-6 · Cited by 5 · see citing works

Diagnostic de la maladie d’Alzheimer : apport de l’imagerie au florbétapir et autres radiopharmaceutiques de la plaque amyloïde

Semah, F., Deberdt, W. G., & Ceccaldi, M. P. (2016) · Médecine Nucléaire · doi:10.1016/j.mednuc.2016.08.001 · Cited by 5 · see citing works

Alzheimer’s disease: a step closer to understanding type 3 diabetes in African Americans

Ferguson, S. A., Panos, J., Sloper, D. T., Varma, V., & Sarkar, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00754-z · Cited by 5 · see citing works

Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimers disease patients: search for a potential biomarker

Emadi, S., Aghababaee, L., & Maghbooli, M. (2016) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20160289 · Cited by 5 · see citing works

Highly sensitive β-amyloid1–42 oligomer aptamer-based assay via dual cyclic amplifications of three-way catalytic hairpin assembly and palindrome polymerase reaction

Yin, Z., Liu, X., Li, S., Yuan, R., & Xiang, Y. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136750 · Cited by 4 · see citing works

Differential Diagnosis of Degenerative Dementias Using Basic Neuropsychological Tests

Jiménez‐Huete, A., Riva, E., Toledano, R., Campo, P., Esteban‐Pérez, J., del Barrio, A., & Franch, O. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514534954 · Cited by 4 · see citing works

Lipidomics

Benedusi, V. (2018) · Materials and Methods · doi:10.13070/mm.en.8.2665 · Cited by 4 · see citing works

Implications of the glymphatic system in the diagnostic and surgical workup of normal pressure hydrocephalus

Broggi, M. A., Barbieri, E. M., Gans, A., Pascuzzo, R., Redaelli, V., Aquino, D., Restelli, F., Schiariti, M. P., Acerbi, F., Fede, G. D., et al. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08308-2 · Cited by 3 · see citing works

Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen

Wiltfang, J. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4086-7 · Cited by 3 · see citing works

Tibetan medicine "RNSP" in treatment of Alzheimer disease.

Shi, J., He, X., Lian, H.-J., Yuan, D., Hu, Q. Y., Sun, Z.-Q., Li, Y.-S., & Zeng, Y.-W. (2015) · PubMed Central · Cited by 3 · see citing works

Gut Microbiota, a Key Factor Relating Diet and Inflammation with the Progression of Cognitive Impairment in Older People

Pérez‐Martínez, G. (2017) · Journal of Nutritional Health & Food Engineering · doi:10.15406/jnhfe.2017.06.00192 · Cited by 2 · see citing works

A Global Review on Alzheimer’s Disease

Natarajan., P., Mumthaj., P., Vijay., J., & Gokul., V. (2021) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2021.v68i01.017 · Cited by 2 · see citing works

Evaluating the predictive power of multivariate tensor-based morphometry in Alzheimer's disease progression via convex fused sparse group Lasso

Tsao, S., Gajawelli, N., Zhou, J., Shi, J., Ye, J., Wang, Y., & Leporé, N. (2014) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2042720 · Cited by 2 · see citing works

Liquorbiomarker zur Frühdiagnostik der Alzheimerdemenz

Wiltfang, J. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000675 · Cited by 2 · see citing works

Single administration of a novel γ-secretase modulator ameliorates cognitive dysfunction in aged C57BL/6J mice

Hayama, T., Murakami, K., Watanabe, T., Maeda, R., Kamata, M., & Kondo, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.020 · Cited by 2 · see citing works

Actitudes, dudas y conocimientos de los colectivos implicados en la atención del paciente con Alzheimer: resultados de la encuesta del proyecto kNOW Alzheimer

Álvarez, P. M.-L. (2016) · Farmacéuticos Comunitarios · doi:10.5672/fc.2173-9218.(2016/vol8).001.03 · Cited by 2 · see citing works

Salivary -42, IGF-I, IGF-II, Alpha Amylase, IL-1, And TNF-alpha In Alzheimer's Disease: A Useful Diagnostic Tool

Singhal, R. K., & Anand, S. (2013) · Cited by 1 · see citing works

Imaging Alzheimer's Disease: The Evolution of Biomarkers

de Leon, M. J., Glodzik, L., Mosconi, L., Osorio, R. S., Kamer, A. R., Santi, S. D., Shulman, M. B., Li, Y., Tsui, W., Butler, T., et al. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00069-5 · Cited by 1 · see citing works

The Development of Novel Proteasome Inhibitors for the Treatment of Multiple Myeloma and Alzheimer's Disease

Lee, M. J. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.169 · Cited by 1 · see citing works

Organische (und symptomatische) psychische Störungen

Hüll, M., & Förstl, H. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-22485-0.00008-7 · Cited by 1 · see citing works

Modeling the Early Identification and Intervention of Alzheimer’s Disease

Michaud, T. L. (2015) · University of Minnesota Digital Conservancy (University of Minnesota)

Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen

Psychiatrie, K. F. (2014)

Review Article Tibetan medicine "RNSP" in treatment of Alzheimer disease

Shi, J., He, X., Lian, H.-J., Yuan, D., Hu, Q. Y., Sun, Z., Li, Y., & Zeng, Y.-W. (2015)

Einfluss selektiver Serotonin-Wiederaufnahmehemmer auf den kognitiven Abbau und die Wahrscheinlichkeit einer Progression zur Alzheimer-Demenz bei älteren Patienten mit Vorgeschichte einer Depression

Klabisch, K. S. (2019) · doi:10.53846/goediss-7288

Bioanalysis of biomarkers in support of drug discovery and development

Drexler, D. M., Olah, T. V., Reily, M. D., Shipkova, P. A., Soares, H. D., & Tymiak, A. A. (2014) · doi:10.4155/fseb2013.13.4

Long-read sequencing reveals two common APOE ε3 and ε4 intragenic haplotypes in the Spanish populationPreprint

García‐González, P., Puerta, R., Muñoz-Morales, Á., Olivé, C., Calm, B., Montrreal, L., Valenzuela, A., Bayón-Buján, P., Rovira, M., Capdevila-Bayo, M., et al. (2025) · medRxiv · doi:10.1101/2025.03.25.25324541

Prospecting salivary tau as a diagnostic for Alzheimer’s type dementia

Santos, G. A. A. D., Vale, F. D. A. C. D., & Fazan, V. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0253 · Cited by 2 · see citing works

Additional file 1 of Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment

Ahmad, S., Yang, W., Orellana, A., Frölich, L., de Rojas, I., Cano, A., Boada, M., Hernández, I., Hausner, L., Harms, A. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26755654

Additional file 2 of Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment

Ahmad, S., Yang, W., Orellana, A., Frölich, L., de Rojas, I., Cano, A., Boada, M., Hernández, I., Hausner, L., Harms, A. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26755657

Biological markers of Alzheimer?s disease

de Souza, L. C., Sarazin, M., Teixeira, A. L., Caramelli, P., dos Santos, A. M., & Dubois, B. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease

Blennow, K., Vanmechelen, E., & Hampel, H. J. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 263 · see citing works

The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s Disease

Engelborghs, S., & Bastard, N. L. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/bf03262201 · Cited by 20 · see citing works

Diagnostic Tools: Fluid Biomarkers for Alzheimer’s Disease

Zetterberg, H., Hampel, H. J., & Blennow, K. (2012) · Advances in biological psychiatry · doi:10.1159/000335385

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis

Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170680 · Cited by 132 · see citing works